NASDAQ:CTIC • US12648L6011
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CTI BIOPHARMA CORP (CTIC).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-05-24 | JMP Securities | Maintains | Market Perform |
| 2023-05-16 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2023-05-15 | Stifel | Downgrade | Buy -> Hold |
| 2023-05-11 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2023-05-11 | Needham | Downgrade | Buy -> Hold |
| 2023-04-19 | Needham | Reiterate | Buy |
| 2023-04-17 | TD Cowen | Maintains | Outperform |
| 2023-03-07 | JMP Securities | Reiterate | Market Outperform |
| 2023-03-06 | Needham | Reiterate | Buy |
| 2023-02-06 | JMP Securities | Reiterate | Market Outperform |
| 2022-10-17 | SVB Leerink | Initiate | Outperform |
| 2022-09-01 | JP Morgan | Initiate | Buy |
| 2022-09-01 | Jefferies | Initiate | Buy |
| 2022-08-09 | JMP Securities | Maintains | Market Outperform |
| 2022-08-09 | Needham | Maintains | Buy |
| 2022-07-07 | Cowen & Co. | Initiate | Outperform |
| 2022-03-02 | JMP Securities | Maintains | Market Outperform |
| 2022-03-02 | Needham | Maintains | Buy |
| 2021-12-01 | Needham | Maintains | Buy |
| 2021-08-09 | BTIG | Initiate | Buy |
| 2021-05-06 | Stifel | Initiate | Buy |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | -100.00% | 53.948M | 127.1M 135.60% | 257.94M 102.94% | 345.55M 33.97% | 473.77M 37.11% | 553.52M 16.83% | 469.3M -15.22% | 537.64M 14.56% | 600.47M 11.69% | ||
| EBITDA YoY % growth | -43.04M -9.32% | -94.806M -120.27% | -77.846M 17.89% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -43.57M -9.14% | -95.332M -118.80% | -79.797M 16.30% | -23.106M 71.04% | 87.327M 477.95% | 162.45M 86.02% | 214.31M 31.92% | 315.74M 47.33% | 276.01M -12.58% | 334.66M 21.25% | 388.21M 16.00% | |
| Operating Margin | N/A | N/A | -147.91% | -18.18% | 33.86% | 47.01% | 45.24% | 57.04% | 58.81% | 62.25% | 64.65% | |
| EPS YoY % growth | -0.69 | -1.08 -56.52% | -0.85 21.30% | -0.28 66.63% | 0.40 242.63% | 0.67 64.87% | 1.04 55.58% | 1.60 54.30% | N/A | N/A | N/A |
All data in USD
| Q2 / 23 | Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 61.35% | -0.06 53.97% | -0.03 75.10% | -0.01 85.72% | 0.01 118.22% | 0.04 168.18% | 0.06 284.37% |
| Revenue Q2Q % growth | 28.221M 128.90% | 32.424M 77.75% | 36.98M 75.40% | 39.399M 63.37% | 45.284M 60.46% | 51.338M 58.33% | 56.8M 53.60% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.18M 61.97% | -3.926M 67.86% | 181.999K 101.34% | 2.678M 129.01% | 7.644M 206.46% | 13.017M 431.53% | 17.679M 9,613.81% |
All data in USD
14 analysts have analysed CTIC and the average price target is 10.7 USD. This implies a price increase of 17.66% is expected in the next year compared to the current price of 9.09.
CTI BIOPHARMA CORP (CTIC) will report earnings on 2023-08-07, after the market close.
The consensus EPS estimate for the next earnings of CTI BIOPHARMA CORP (CTIC) is -0.08 USD and the consensus revenue estimate is 28.22M USD.
The consensus rating for CTI BIOPHARMA CORP (CTIC) is 75.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.